Outlook Therapeutics, Inc.於2010年1月5日在新澤西州註冊成立。該公司是一家生物製藥公司，在歐盟或歐盟、英國或英國率先獲得ONS-5010/LYTENAVA（貝伐珠單抗-gamma）眼科製劑上市許可，用於治療濕性年齡相關性黃斑變性，或濕性AMD。該公司正在開發ONS-5010/LYTENAVA，作為玻璃體內注射液給藥，用於治療濕性AMD和視網膜疾病。
董事
名稱
職位
C. Russell Trenary III
President, Chief Executive Officer and Director
Ralph H. Thurman
Executive Chairman of the Board, Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
Andong Huang
Director
Faisal G. Sukhtian
Director
Gerd Auffarth
Director
Julia A. Haller
Director
Julian Gangolli
Director
Kurt J. Hilzinger
Director
Yezan Haddadin
Director
股東
名稱
職位
C. Russell Trenary III
President, Chief Executive Officer and Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director